CT-076

N/A

Report date: 2025/04/24 15:28:40

Base Information

Drug NameCT-076

Drug Alias NameCT-076

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionClaudin-18 splice variant 2 binders

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShenzhen Celconta Life Science Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Celconta Life Science Co Ltd

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A